Pharmacokinetics of β-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
暂无分享,去创建一个
S. Ewings | L. Dickinson | H. Reynolds | W. Holman | W. Painter | L. Else | S. Khoo | A. Amara | S. Dilly Penchala | L. Walker | R. Lyon | C. Hale | V. Shaw | T. Fletcher | W. Greenhalf | L. Lavelle-Langham | G. Griffiths | R. Fitzgerald
[1] S. Khoo,et al. The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva , 2021, Journal of pharmaceutical and biomedical analysis.
[2] W. Greenhalf,et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study , 2021, The Journal of antimicrobial chemotherapy.
[3] Munir Pirmohamed,et al. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter , 2021, Trials.
[4] G. Painter,et al. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2 , 2021, Antimicrobial Agents and Chemotherapy.
[5] R. Plemper,et al. Therapeutically Administered Ribonucleoside Analogue MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets , 2020, Nature microbiology.
[6] R. Vunnam,et al. Transmission of SARS-CoV-2: an update of current literature , 2020, European Journal of Clinical Microbiology & Infectious Diseases.
[7] Xiaotao Lu,et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice , 2020, Science Translational Medicine.
[8] A. Kolykhalov,et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. , 2019, Antiviral research.
[9] L. Stuyver,et al. Metabolism of the Anti-Hepatitis C Virus Nucleoside β-d-N4-Hydroxycytidine in Different Liver Cells , 2004, Antimicrobial Agents and Chemotherapy.
[10] R. Haeckel. Factors Influencing the Saliva/Plasma Ratio of Drugs , 1993, Annals of the New York Academy of Sciences.